Citigroup
CCCC icon

Citigroup’s C4 Therapeutics CCCC Stock Holding History

Citigroup’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,600
Closed -$41.8K – 5622
2024
Q4 		$41.8K Buy
+11,600
New +$57.7K ﹤0.01% 5133

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's CCCC Position: Q1 2026 in Review

Citigroup reduced its C4 Therapeutics (CCCC) stake by 15% in Q1 2026, selling an estimated $17.5K and leaving 42,428 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #4239.

Citigroup first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $6.3M in Q1 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Citigroup held 42,428 shares of C4 Therapeutics worth $112K as of Q1 2026.
  • Citigroup sold 7,412 C4 Therapeutics shares in Q1 2026, an estimated $17.5K.
  • C4 Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4239 holding.
  • Citigroup first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's C4 Therapeutics position peaked at $6.3M in Q1 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.